Cited 21 times in
Radiotherapeutic strategies in the management of hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성진실 | - |
dc.contributor.author | 이익재 | - |
dc.date.accessioned | 2014-12-20T17:36:42Z | - |
dc.date.available | 2014-12-20T17:36:42Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94929 | - |
dc.description.abstract | Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 123~133 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Benzenesulfonates/therapeutic use | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/radiotherapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/therapy | - |
dc.subject.MESH | Chemoembolization, Therapeutic | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver/pathology | - |
dc.subject.MESH | Liver Neoplasms/pathology | - |
dc.subject.MESH | Liver Neoplasms/radiotherapy* | - |
dc.subject.MESH | Liver Neoplasms/therapy | - |
dc.subject.MESH | Niacinamide/analogs & derivatives | - |
dc.subject.MESH | Phenylurea Compounds | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Pyridines/therapeutic use | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Radiotherapeutic strategies in the management of hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | Lee I.J. | - |
dc.contributor.googleauthor | Seong J. | - |
dc.identifier.doi | 10.1159/000333275 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A03055 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 22212946 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/333275 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Sorafenib | - |
dc.subject.keyword | Radiotherapy | - |
dc.subject.keyword | Transarterial chemoembolization | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Lee, Ik Jae | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Lee, Ik Jae | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 81 | - |
dc.citation.number | Suppl 1 | - |
dc.citation.startPage | 123 | - |
dc.citation.endPage | 133 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.81(Suppl 1) : 123-133, 2011 | - |
dc.identifier.rimsid | 26924 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.